SKIP1 Antibody
Description
SKP1 Antibody Characteristics
SKP1 antibodies are polyclonal or monoclonal reagents designed to detect endogenous SKP1 protein across species. Key features include:
Biological Role of SKP1
SKP1 serves as a scaffold for the SCF complex, enabling substrate recognition by F-box proteins (e.g., β-TrCP, SKP2) and subsequent ubiquitination. Key functions include:
-
Cell Cycle Regulation: Targets proteins like p27 for degradation to promote cell cycle progression .
-
DNA Damage Response: Modulates p21 levels, influencing p53-mediated apoptosis .
-
Lysosome Positioning: Interacts with kinesin-1 to regulate lysosome dispersion via phosphorylation .
A. Recommended Dilutions
| Application | Dilution Range |
|---|---|
| Western Blot (WB) | 1:500–1:1,000 |
| Immunohistochemistry | 1:50–1:500 |
| Immunofluorescence | 1:50–1:200 |
B. Tested Reactivity in Key Studies
| Application | Positive Detection |
|---|---|
| WB | HeLa cells, human brain tissue, MCF-7 cells |
| IHC | Human gliomas, lung cancer (antigen retrieval recommended) |
| IF/ICC | HepG2 cells |
A. SKP1 in Cancer Biology
-
p21 Regulation: SKP1 depletion reduces p21 protein levels, sensitizing cancer cells to p53-mediated apoptosis under DNA damage .
-
Phosphorylation Dynamics:
B. Mechanistic Insights
| Interaction Partner | Functional Outcome |
|---|---|
| U2AF65 | Recruited to p21 gene for mRNA splicing |
| Kinesin-1 | Drives lysosome dispersion via WD motif binding |
| PPM1B | Dephosphorylates SKP1 to regulate CRL1 activity |
Therapeutic Implications
SKP1 is implicated in cancer progression and drug resistance:
-
Targeting SKP1-SCF Complexes: Inhibitors of SKP1-F-box interactions (e.g., brusatol) show efficacy in non-small cell lung cancer by reducing metastasis .
-
Ubiquitination Pathways: SKP1-mediated degradation of oncoproteins (e.g., PLK1) is explored for liver cancer therapy .
Future Directions
Product Specs
Constituents: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
